Farther Finance Advisors’s Virax Biolabs VRAX Stock Holding History

Farther Finance Advisors’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$4	–	6121
2026 Q1	$4	Hold	1	–	–	﹤0.01%	5719
2025 Q4	$7	Hold	1	–	–	﹤0.01%	5422
2025 Q3	$13	Buy	+1	New	+$19	﹤0.01%	4920

Farther Finance Advisors's VRAX Position: Q2 2026 in Review

Farther Finance Advisors sold out of Virax Biolabs (VRAX) in Q2 2026, closing a stake of 1 share — an estimated $4 sold.

Farther Finance Advisors first reported a position in VRAX in Q3 2025 and held it in 3 quarters. The position peaked at $13 in Q3 2025. 0 funds tracked by Wall St. Rank hold VRAX as of Q2 2026.

Farther Finance Advisors reported no remaining Virax Biolabs position as of Q2 2026 after selling out during the quarter.
Farther Finance Advisors sold 1 Virax Biolabs share in Q2 2026, an estimated $4.
Farther Finance Advisors first reported a position in Virax Biolabs in Q3 2025 and held it in 3 quarters.
Farther Finance Advisors's Virax Biolabs position peaked at $13 in Q3 2025.
0 funds tracked by Wall St. Rank held Virax Biolabs as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.